Pipex Pharma --- Von OTC zu AMEX (1A Biotech) - 500 Beiträge pro Seite

[BrauchGeld]

Wir sehen hier wohl eines der unterbewertesten US-Biotech überhaupt ,das liegt wohl daran das Pipex Pharma erst seit einigen monaten in dieser form exestiert (merger mit Sheffield Pharma 6.Nov 2006).
Pipex Pharma hat ein marktreifes produkt(Coprexa) das zwei PhaseIII tests erfolgreich bestanden hat, NDA filing ist für Oktober 2007 geplant und könnte somit im 3Q 2008 zugelassen werden.
Und auch der rest der pipeline ist mehr als gigantisch einige davon mit Blockbuster potential (Alzheimer,Multiple sklerose usw).
Im vorfeld der Amex notierung hat sich der CEO mit über 100tsd aktien (kk:~5,30$) eingedeckt also deutlich über den aktuellen kurs.
Es gibt noch keine empfehlungen für Pipex und auch die Großinvestoren fehlen ,das alles wird sich mit der Amex listing sicher ändern.

Ich halte Pipex für sehr aussichtsreich deshalb hab ich mir zunächst 3000st. zu 4$ gekauft .

Pipex Pharma (PPEX.OB)--> ab 26.6 (Amex: PP)
Marktkap: 66,4 mio$
Cash: 11 mio$
Shares Out: 17 mio aktien
Kurs: 3,90 $

Rodman 14.Mai 2007:
http://www.wsw.com/webcast/rrshq11/ppxp/



Homepage:
http://www.pipexpharma.com/

[BrauchGeld]

Netter Artikel ...........

"The Big Picture"

CEO of Tiny Drug Company Buys Big Position Just Ahead of Move to American Stock Exchange

By Michael Brush
Exclusively for InvestorIdeas.com
April 19, 2007

Pipex Pharmaceuticals (PPXP) is a grad school professor’s dream.

Founded by a venture capitalist, the company hunts at universities for promising drugs, locks them up in license agreements, and then funds their development to bring them to market.

Earlier this week co-founder and chief executive Steve Kanzer plowed about a half million dollars into the stock at an average of around $2.06 per share.

The timing is interesting, because the company is about to get approve for listing on the American Stock Exchange and move off the bulletin board.

There’s no guarantee the stock will pop on this move – but it might. However, we’re not really traders here at Insiders Corner so what’s more important is the medium term. In that time frame, the transfer to the American Stock Exchange is also a big positive because it will mean more institutions can buy Pipex and more analysts can pick up coverage.

Kanzer’s purchase this week is also interesting because as co-founder he already has a lot of exposure to the company. And the purchase can’t be read as an effort to juice the shares ahead of a financing deal since Pipex just raised $13.9 million late last year.

With a projected cash burn rate of $6 million a year, that should carry it through to early stage profitability when its first drug gets launched in early 2008, says the company. Here’s a closer look.

The big picture

Pipex likes to focus on diseases for which there aren’t very good treatments around -- like lung fibrosis and multiple sclerosis (MS). Pipex also develops drugs that are already in use in other parts of the world for decades – so their safety and risk profiles are well known.

Both factors could help the company get faster approval of drugs by the Food and Drug Administration (FDA), so they can bring them to market quicker. Here’s where Pipex might make progress.

Too much copper

The company’s lead drug, Coprexa, could be on the market as early as the first quarter of 2008 as a treatment for a neurological disorder called Wilson’s Disease.

Like many of the diseases that Coprexa may eventually treat, Wilson’s Disease is a disorder caused by elevated levels of “free copper” in the blood. “Free copper” is the toxic form of copper -- not to be confused with the essential form which is found tightly bound to proteins in the blood. The problem with free copper is that it readily crosses the blood-brain barrier, and the brain is highly sensitive to its toxic effects.

In Wilson’s Disease, for example, free copper causes psychosis-like symptoms including loss of emotional control, temper tantrums, severe depression, suicidal thoughts, delusions, and hallucinations. Without treatment, this horrible disease usually kills its victims by 30. Phase III testing suggests Coprexa treats the disease by lowering the levels of free copper in blood. Pipex is now writing the new drug application for this use of Coprexa, and it may be on the market for this use in early 2008.

There could be other applications down the road. For example, Coprexa may work against idiopathic pulmonary fibrosis. This lung disease takes about 30,000 people a year -- or more than breast cancer and prostate cancer. There is no FDA approved therapy.

Animal tests have shown that Coprexa inhibits lung fibrosis. Again, it works by reducing free copper in the blood, which is thought to play a role in lung fibrosis. Pipex has completed phase II testing for this use.

Coprexa may also work against Alzheimer’s, another disease linked to excessive free copper in the blood. Pipex just got a $306,000 grant to study the use of Coperxa against this ailment.

Multiple sclerosis

Another Pipex compound called Trimesta has been used in Europe to treat hot flashes for 40 years. Researchers think Trimesta, a form of estriol that can be taken orally, may also work against autoimmune diseases like MS.

Here’s why. Women with autoimmune diseases like MS typically see their symptoms subside during pregnancy, especially in the third trimester. It could be because estriol levels rise in women during pregnancy. (Estriol immunizes the fetus against rejection by the mother.)

Phase II studies by Pipex have shown that Trimesta reduces lesions associated with MS, a neurological disease in which the body loses the ability to transmit messages along nerve cells. This causes a loss of muscle control, paralysis, and even death. MS afflicts about 400,000 people in the U.S., and it weighs heavily on the health care system, costing more than $9 billion a year including lost wages. Pipex has another early-stage compound that may work against MS called Anti-CD4 802-2.

A pain therapy

Another Pipex compound called Effirma may be effective against a pain disorder called Fibromyalgia. Effirma has been used in Europe to treat lower back pain since 1984. Pipex is in the process of planning phase II trials for use in the U.S.

The bottom line : Pipex is a tiny $116 million market cap company that’s off the radar screen for many investors because it’s hidden on the bulletin board. That’s about to change as the company graduates to the American Stock Exchange. Pipex is also about to publish results on how Coprexa works against fibrosis, which could also serve as a catalyst. These factors may explain why the company’s CEO just plunked down a half a million dollars on the stock even though he’s already got plenty of exposure. I’d follow him into the stock right now with at least a two-year time horizon.

[BrauchGeld]

http://biz.yahoo.com/iw/070611/0264324.html

Pipex Pharmaceuticals' Oral TRIMESTA Initiates Enrollment of Phase II/III Clinical Trial for Multiple Sclerosis
Monday June 11, 7:45 am ET

$5 Million Grant From National Multiple Sclerosis Society, With Support From NIH

Previous Phase II Demonstrated 79% Reduction in Gadolinium Enhancing Brain (MS Lesion) Volumes (p=0.02) and Exceptional 14% Increase in Cognitive Function (p=0.04)

[invest2002]

[Morgenrte]

...die haben abe nur 8 (!) Mitarbeiter - wie seriös ist das Ganze wirklich?!

[Csillagok]

Würd mal sagen :

PUSHER-ALAAAAAAAAAAAAAAAAAAAAAARM !!!!!!!!!!!!!!!!

[Joe_Trader]

Antwort auf Beitrag Nr.: 30.276.329 von Morgenrte am 24.06.07 17:21:15

Unter den drei führenden amerikanischen Börsen NASDAQ, NYSE und AMEX ist letztere für weniger strikte Kriterien zur Aufnahme von Unternehmen bekannt d.h. sind die meisten gehandelten Firmen kleiner als an den anderen Börsen. Der Hauptteil der amerikanischen Indexaktien wird am AMEX gehandelt.

[Joe_Trader]

Antwort auf Beitrag Nr.: 30.276.634 von Joe_Trader am 24.06.07 17:28:56

wenn man ein Ranking bei den USA Börsen durchführt, würde die Amex
auf den dritt schlechsten Platz kommen, aber immer noch vor Pink Sheet und der OTC

also seriöser und sicherer als die OTC und Pink Sheet Werte dürfte eine dort gelistete Firma schon sein.

Das hilft aber nicht bei der Frage weiter, wie sicher wäre ein Invest bei der Firma ?

Auch an der Amex kann eine faule Bohne drin sein.

[Joe_Trader]

Antwort auf Beitrag Nr.: 30.276.407 von Csillagok am 24.06.07 17:23:28

na na

[Joe_Trader]

Antwort auf Beitrag Nr.: 30.272.042 von BrauchGeld am 24.06.07 14:49:11

@ BrauchGeld vielleicht wäre ein Invest in die von mir vorgestellte Aktie CORCEPT THERAPEUTICS INC
WKN Nasday = cort doch sicherer,welche du ja als überteuert und sagen wir mal nicht "Zukunfssicher" bezeichnet hast doch besser.
ach weist du was, ich kopiere einfach mal dein Posting hier hinein.

-----------------------------------------------------------
#8 von BrauchGeld Benutzerinfo Nachricht an Benutzer Beiträge des Benutzers ausblenden 22.06.07 21:55:50 Beitrag Nr.: 30.156.557
Dieses Posting: versenden | melden | drucken | Antwort schreiben | CORCEPT THERAPEUTICS INC
ChartNewsNews einen Beitrag nach oben
einen Beitrag nach unten

Folgende Antwort bezieht sich auf Beitrag Nr.: 30.156.391 im neuen Fenster öffnen von Joe_Trader am 22.06.07 21:43:52 Das geld wird aber lange vor den ergebnissen weg sein,Phase 3 startet ja erst im 3Q oder 4Q .

Diese Aktie wirst du schon bald viel billiger bekommen selbst dann würde ich nicht so einen schrott kaufen.
----------------------------------------------------------------

so, jetzt vergleiche doch mal deine Aktie mit Corcept Therapeutics

[BrauchGeld]

@Morgenrte
Was nützen 50 oder gar 100 mitarbeiter wenn die trotzdem nichts zustande bringen, Pipex hat zwar nur wenige mitarbeiter aber dafür hochqualifiziert.

@Csillagok
Die Aktie hat es nicht nötig gepusht zuwerden .

Ich glaube kaum das jemand über eine halbe million dollar in ein unternehmen investiert wenn er nicht wüsste das da mehr zuholen ist das ist zwar keine garantie für den erfolg aber ein gutes zeichen.
Und das sich 70% der 17mio aktien in festen händen befinden ist für mich auch sehr positiv.


I-hub board:
http://www.investorshub.com/boards/board.asp?board_id=7393

Pipex Pharmaceuticals ramps up drug development
Posted by Sonja Brodie / Ann Arbor Business Review April 12, 2007 09:45AM
A lot of things are happening at Ann Arbor-based Pipex Pharmaceuticals Inc. [OTCBB: PPXP].

The specialty pharmaceutical company will be listed on the American Stock Exchange at the end of the month and it has recently leased space in Ann Arbor to manufacture its lead drug candidate, which is on course for FDA approval by the second quarter of 2008.

Pipex is developing proprietary, late-stage drugs for the treatment of neurological and autoimmune diseases. The company's strategy is to exclusively license proprietary, clinical-stage drug candidates that have demonstrated clinical efficacy and to complete further clinical testing and manufacturing sufficient to seek marketing authorizations with the Federal Drug Administration and the European Medicines Evaluation Agency.

The company's lead drug candidate is Coprexa, an oral anti-copper medicine that has completed two phase III clinical trials in Wilson's disease patients, who suffer from having copper accumulate in their tissues, causing liver disease and neurological symptoms.

Pipex expects to file its new drug application for Coprexa by October, CEO Steve H. Kanzer said. The approval process can take six to 10 months and he expects Coprexa to be FDA-approved by the second quarter of 2008.

The company plans to establish an in-house neuroscience sales and marketing department to market the drug next year.

The firm also is trying to find additional applications for Coprexa, including as treatment for Alzheimer's disease; primary biliary cirrhosis, which is an autoimmune disease of the liver; and idiopathic pulmonary fibrosis, a lung disease.

In February, the National Institute of Health granted $306,172 to support the testing of Coprexa's suitability for the treatment of Alzheimer's.


Other endeavors

Among Pipex's other drug developments are a multiple sclerosis therapy called Trimesta, a pouchitis medicine called Correcta and a fibromyalgia treatment called Effirma.

Pipex contracts with manufacturing firms to produce the bulk of active ingredients for its drugs.

According to a recent SEC filing, the company leased a 6,000-square-foot facility in Ann Arbor in January and plans to manufacture Coprexa initially at the site. Kanzer said the company would release details - including the location - in late April.

Since September 2005, the 11-employee firm has had a collaborative research and development agreement with the University of Michigan, from which it also exclusively licenses a patent relating to anti-copper therapeutics.

It also has agreements with several other institutions, including McLean Hospital at Harvard University, the University of Southern California and Children's Hospital-Boston.


Partnerships

To find partners and potential drugs to develop, "we look through all the clinical work at universities, we look at NIH grants. It's a pretty exhaustive process," Kanzer said. "All of the drug candidates are in phase II and almost all come from universities."

Pipex Pharmaceuticals Inc. [OTCBB: PPXP] has just issued its first financial report since going public last November via a reverse merger with the former Sheffield Pharmaceuticals Inc.

At the end of 2006, the company had about $12.2 million of cash and $11.5 million of working capital, compared with $1.1 million of cash and working capital of ($985,968) on Dec. 31, 2005.

It attributed the $11.1 million increase primarily from the net proceeds from a $13.9 million private equity financing in the fourth quarter of 2006.

[BrauchGeld]

@joe_trader

Nochmal extra für dich Pipex hat schon ein produkt erfolgreich durch alle testphasen gebracht alleine das macht Pipex wesentlich interessanter als Corcept das sogut wie nichts in der pipeline hat und falls Corlux wieder versagt kannst Du dich von deinem geld verabschieden .

Damit ist auch wieder bewiesen das schrott überall gehandelt wird egal ob otc,amex oder nasdaq usw.

[Joe_Trader]

Antwort auf Beitrag Nr.: 30.279.315 von BrauchGeld am 24.06.07 18:32:21

okay unentschieden

[BrauchGeld]

Ab Dienstag beginnt hoffentlich die positive performance bei dieser unterbewertung wird das sicher nicht lange dauern.

Damit es keine verwirrung mit den zahlen gibt ,Pipex hat vor 2 monaten einen 1:3 reverse split durchgeführt.

Pipex Pharmaceuticals, Inc. Completes Reverse Stock Split and New ...

ANN ARBOR, MI -- (MARKET WIRE) -- 04/25/07 -- Pipex Pharmaceuticals, Inc. (the "Company" or "Pipex") (OTCBB: PPEX), a specialty pharmaceutical company developing innovative late-stage oral drug candidates for the treatment of neurologic and fibrotic diseases, announced today that in preparation for a proposed listing on the American Stock Exchange (AMEX), it has completed the previously disclosed reverse stock split of Pipex's common stock on a 1:3 basis. As a result of the reverse split, Pipex now has approximately 16.9 million shares outstanding and the Over-The-Counter Market on the NASD Electronic Bulletin Board (OTCBB) will begin to trade Pipex's shares of common stock as of today under the new ticker symbol "PPEX."


3M Chart:

[BrauchGeld]

Kurs: 4,20 $

5D Chart:



Pipex Pharmaceuticals, Inc.
Tuesday June 26, 11:08 am ET


NEW YORK, June 26 /PRNewswire/ -- The American Stock Exchange® (Amex®) today listed the common stock of Pipex Pharmaceuticals, Inc. under the ticker symbol PP.
Pipex Pharmaceuticals, Inc. is a development-stage, specialty pharmaceutical company that is developing proprietary, late-stage drug candidates for the treatment of neurologic and fibrotic diseases.

"We are pleased to welcome Pipex Pharmaceuticals to the American Stock Exchange," said John McGonegal, Senior Vice President of the Amex Equities Group. "We look forward to working with an innovative company like Pipex Pharmaceuticals and providing them with the solid support and services that are essential in today's competitive marketplace."

"We are very delighted to be listed on the American Stock Exchange," said Steve H. Kanzer, Pipex's co-founder, Chairman and Chief Executive Officer. "We believe this Amex listing will provide our current and future shareholders with a greater degree of visibility and liquidity as Pipex proceeds to an NDA filing and commercialization, for COPREXA for the treatment of neurologic Wilson's disease and our planned randomized, multicenter placebo-controlled trial of COPREXA for idiopathic pulmonary fibrosis (IPF)."

[BrauchGeld]

Ein artikel über den erfolgreichen Pipex präsident und Holocaust-überlebender Dr.Bisgaier:

http://blog.mlive.com/ann_arbor_news_extra/2007/03/the_9to5_…

The 9-to-5 didn't do it for Pipex's Bisgaier

After Esperion, scientist pursued new research
After spending his teenage years in Nazi Germany's Flossenburg concentration camp, Holocaust survivor Abraham Bisgaier wanted just one thing for his children.

To be able to go to school.

"Education was very important in our family," says Charlie Bisgaier, who calls his late father and mother his greatest mentors. "It was something he wasn't able to have."

With a Ph.D. in biochemistry, Bisgaier no doubt did his parents proud.

Today he's president of Pipex Therapeutics, a young specialty pharmaceutical firm working to develop drugs to treat neurological and autoimmune diseases like Wilson's disease, Alzheimer's disease and multiple sclerosis.

"I find it very exciting to work here, although the business world is very different from the scientific world," said Bisgaier, who spent most of his career in the lab as a research scientist. "There are more things to do than hours in the day."

Born in the Bronx of New York City, Bisgaier, an avid fisherman, attended college in New York and Washington, later studying lipoprotein metabolism at Columbia University.

Columbia colleague Joe Cornicelli persuaded Bisgaier to take a job with Warner-Lambert/Parke-Davis in 1990, which brought him to Ann Arbor. Cornicelli, who's known Bisgaier for 27 years, said his friend is driven by innate curiosity and a passion for applying science to the real world.

"He sees things as a challenge: `I could do that, I could do it better and I could make it happen,"' Cornicelli said. "There's something about going to work and saying `maybe today's the day.' It really is a rush and it really drives Charlie."

In the 1990s, Bisgaier helped develop the blockbuster cholesterol drug Lipitor with Warner-Lambert/Parke-Davis in Ann Arbor before Pfizer Inc. took over. He left there in 1998 to co-found Esperion Therapeutics, a drug company that Pfizer bought for $1.3 billion four years later.

He left Esperion in 2006 to join Pipex.

"It's a scary decision," Bisgaier said. "You are leaving a very secure job and taking a huge risk."

Bisgaier, a father of two, has been married to Pat since 1976. Besides fishing, he skis, golfs and bikes. He gardened for a time, until deer devoured the garden at his Superior Township home.

"It just seems now that I don't have as much free time," Bisgaier said. "A startup company is extremely demanding on your time if you want the venture to be successful."

Bisgaier's daily struggles are similar to what his father went through building a jewelry business as an immigrant in New York.

"He wanted us to get a 9-to-5 type job, to be able to come home and not worry about anything," Bisgaier said. "But I ended up taking after him anyway."

[BrauchGeld]

Schöne entwickelung bisher zwar fehlt das Volumen aber solange die Aktie steigt ist das in ordnung .

Ich höre schon die Kasse klingeln ......

50-Day Moving Average3: 4.39 <<durchbrochen
200-Day Moving Average3: 8.15

Kurs: 4,50 $ (+ 7,1%)

[BrauchGeld]

Unglaublich was man für nur 76 mio$ marktkap kriegt :

Coprexa ( Wilson Disease) NDA für Okt. 2007 geplant

Trimesta (Multiple Sklerose) Phase 2/3 läuft

Coprexa (Pulmonary Fibrosis) startet Phase 2/3 in 2H 2007

und noch einige in Phase 2


Wenn alles gut läuft dürften 15$ - 20$ für die nächsten 12 monate kein problem sein .

[BrauchGeld]

Typisch Pipex immer in der letzten minute wird der kurs hoch gezogen.

Kurs: 4,80 $ ( + 6,6%)
Marktkap: 81 mio$

[BrauchGeld]

Falls Pipex in den nächsten tagen die 100 mio$ marktkap überschreitet dürfte auch das interesse der Institutionellen steigen .
Wenn man bedenkt das rund 12 mio der 17 mio außenstehenden Aktien sich in festen händen befinden ,dann kann man sich in etwa vorstellen wie die Aktie reagieren wird wenn die ersten empfehlungen bzw. instis einsteigen .
In den letzten 7 monate hat Pipex 3 mal den ticker(PPXP.OB ,PPEX.OB und jetzt PP) gewechselt kein wunder das kaum einer diese Aktie kennt .

Kurs: 4,80 $
Marktkap: 81,7 mio$


Seit Amex listing gings nur aufwärts

[BrauchGeld]

[BrauchGeld]

http://www.crainsdetroit.com/apps/pbcs.dll/article?AID=/2007…

Promising prescription: $5.5B market waiting as Pipex tests 2 drugs

By Andrew Dietderich

3:01 am, June 25, 2007

An Ann Arbor-based company that’s moving to the American Stock Exchange today plans to tap at least two drug markets that could be worth a total of $5.5 billion annually, using drugs licensed from the University of Michigan and the University of California at Los Angeles.

Two weeks ago, Pipex Pharmaceuticals Inc. (Amex: PP) received $5 million from the National Multiple Sclerosis Society, the largest grant ever given by the organization.

Pipex has six drugs in its pipeline, but two are closest to going to market: Trimesta and Coprexa.

Trimesta is used to treat multiple sclerosis; and Coprexa is used to treat Wilson’s disease, which destroys the lungs.

Pipex was founded in Miami in 2001 by Steve Kanzer, the company’s chairman and CEO. A biotech investor, Kanzer moved Pipex to Michigan in 2004 to be nearer to the talent pool in Ann Arbor.

“Florida is working on its biotech industry. But there is so much more talent in Michigan, I decided to come here,” he said.

That’s not the only reason, though.

The compound for Coprexa is licensed from UM. Coprexa has been through two clinical trials and treats a disease called idiopathic pulmonary fibrosis — the technical name for Wilson’s disease, which kills about 128,000 people in the United States annually.

“The technology came out of the University of Michigan, so it really speaks to the kind of talent and money that is available in the Ann Arbor area,” said Tim Robinson, vice president of operations at Ann Arbor Spark, the economic development association for the Ann Arbor area.

Kanzer said there is no treatment for Wilson’s disease, and the potential market for the drug is $5 billion annually.

Pipex plans to file its application for approval for Trimesta in late 2009. The drug was discovered by a UCLA researcher who found that a specific hormone in the placenta of pregnant women with multiple sclerosis helped with remission of the disease and reduced lesions in the brain by 80 percent.

The drug, also licensed by Pipex, has completed phase II clinical trials.

Kanzer said the potential U.S. market for that drug is worth $500 million annually.

Pipex completed $13.9 million in private-equity financing in the fourth quarter and went public at the end of April.

Besides UM and UCLA, the company has agreements with McLean Hospital at Harvard University, the University of Southern California and Children’s Hospital-Boston.

Pipex recently completed a new lab in Ann Arbor. The company has 18 employees — four from Esperion Therapeutics Inc., including the co-founder and co-developer of Lipitor, Charles Bisgaier. He is Pipex president and a member of the board.

Pipex has a way to go when it comes to finances, though.

In the first three months of the year, the company reported a net loss of $2.8 million or 90 cents a share. It does research and development and didn’t have any revenue.

[Der.Eroberer]

Pipex Pharmaceuticals' Oral TRIMESTA Initiates Dosing in Phase II/III Clinical Trial for Multiple Sclerosis
Monday July 16, 8:15 am ET


ANN ARBOR, MI--(MARKET WIRE)--Jul 16, 2007 -- Pipex Pharmaceuticals, Inc. (AMEX: PP - News), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced today that it has initiated patient dosing of TRIMESTA (oral estriol), its proprietary therapy for multiple sclerosis (MS), in a multi-center Phase II/III clinical trial for the treatment of women with relapsing-remitting MS. This clinical trial has received a $5 million grant from the National Multiple Sclerosis Society (NMSS) in partnership with the National MS Society's Southern California chapter, with support from the National Institutes of Health (NIH).
ADVERTISEMENT


Dr. Rhonda Voskuhl, professor of neurology at the University of California, Los Angeles and inventor of TRIMESTA, commented, "We are delighted to be enrolling so shortly after recently initiating the Phase II/III clinical trial."

Dr. Charles Bisgaier, Pipex's President, stated, "To our knowledge, this is the first gender-specific, oral, potentially disease-modifying agent that has entered later-stage clinical trials for the treatment of MS."

Dr. Bisgaier went onto say, "Given the convenience of an oral drug therapy, such as TRIMESTA, we have received a lot of positive patient interest in this study and hope to continue enrolling at this positive rate."

The Phase II/III clinical study is a double-blind, placebo-controlled trial that will take place at seven sites in the US and will enroll up to 150 female MS patients. Investigators will administer TRIMESTA along with COPAXONE, an FDA approved therapy for MS to women between the ages of 18-50 who have been recently diagnosed with relapsing-remitting MS.

Previous Phase II Clinical Trial Results in Relapsing Remitting Multiple Sclerosis

TRIMESTA (oral estriol) has completed an initial 22-month, single-agent, crossover Phase II clinical trial in the US for the treatment of MS in relapsing remitting patients, with highly encouraging results. The results showed the total volume and number of enhancing pathogenic myelin lesions (established neuroimaging measurements of disease activity in MS) decreased during the treatment period as compared to a six-month pretreatment baseline period. The median total enhancing lesion volumes decreased by 79 percent (p=0.02) and the number of lesions decreased by 82 percent (p=0.09) within the first three months of treatment with TRIMESTA.

Following a six-month drug holiday during which the patients weren't on any drug therapies, TRIMESTA therapy was reinitiated during a four-month retreatment phase of this clinical trial. The relapsing-remitting MS patients again demonstrated a decrease in enhancing lesion volumes of 88 percent (p=0.008) and a decrease in the number of lesions by 48 percent (p=0.04) compared with original baseline scores (1),(2).

Improvement in Cognitive Testing Scores

During this Phase II clinical trial, a 14-percent improvement in Paced Auditory Serial Addition Test ("PASAT") cognitive testing scores (p=0.04) was also observed in the MS patients at six months of therapy. PASAT is a routine cognitive test performed in patients with a wide variety of neuropsychological disorders such as MS. The PASAT scores were expressed as a mean percent change from baseline and were significantly improved in the relapsing-remitting group.

About The TRIMESTA Phase II/III Study

TRIMESTA will be given in combination with subcutaneously injected Copaxone®, a standard treatment for MS. The team will evaluate effects of the treatment combination on relapse rates by using several clinical and magnetic resonance imaging measures of disability progression

The study sites include the University of California, Los Angeles (UCLA), Ohio State University (OSU), Rutgers University (UMDNJ), Washington University, St. Louis, University of Chicago, University of Utah, and Wayne State University. For further information on this Phase II/III clinical trial, please visit http://clinicaltrials.gov/ct/show/NCT00451204.

[Der.Eroberer]

Wer hat denn da heute seine 715 St von gestern wieder entsorgt???

Wenn das mal nicht zu früh war...

PP wird langsam entdeckt und wird bald nicht mehr unter 4 Euro zu haben sein.

[BrauchGeld]

War eine woche in urlaub und freue mich sehr das Pipex sich sogut entwickelt hat .

Kanzer und Bisgaier haben nochmal kräftig zugeschlagen ,Kanzer hält inzwischen knapp 8 mio aktien .

http://finance.yahoo.com/q/it?s=PP

July 10, 2007 - INITIATION

Pipex Pharmaceuticals (PP)

BUY – Phase 3 data in hand justify upside; free option on potential blockbusters



WILSON’S DISEASE JUSTIFIES PP UPSIDE BY ITSELF; PHASE 3 DATA IN HAND
First opportunity for PP’s lead drug, Coprexa—Wilson’s disease, an orphan indication—is not priced in despite positive Phase 3 data

POSITIVE PROOF-OF-CONCEPT DATA IN HAND FOR ORAL ESTRIOL IN MS
Potentially pivotal 2-year trial of Trimesta began June-07; trial also has 1-year endpoint; oral multiple sclerosis drug could be blockbuster

POSITIVE PROOF-OF-CONCEPT DATA IN HAND FOR COPREXA IN IPF
Potentially pivotal one-year trial to begin 2H07; oral idiopathic pulmonary fibrosis drug could be blockbuster

OTHER POTENTIAL BLOCKBUSTERS’ PROOF-OF-CONCEPT DATA SOON
802-2 for autoimmune disorders, Effirma for fibromyalgia; both are potential blockbusters currently in or entering proof-of-concept trials; pipeline also includes several other drugs for smaller indications and/or in earlier stages of testing

’07 $6.50 WILSON’S ONLY PRICE TARGET
2011/2012 targets, based on only Coprexa in Wilson’s disease, yield $6.50 ’07 price target when annually discounted at 22.5%; free option on pipeline full of ’07-’09 catalysts


http://ichart.finance.yahoo.com/w?s=PP

[BrauchGeld]

In den letzten 5 tage hat der CEO für weitere 500.000 US$ aktien von seinem Unternehmen gekauft.

50-Day Moving Average3: 4.48
200-Day Moving Average3: 7.17 << nächstes ziel

Kurs: 6$ (tageshoch 6,37$)
Marktkap: 102 mio$

[BrauchGeld]

Das dürfte auch einen kleinen auftrieb geben......

PP in Business Week pg 84 this week.....

A Promising Pipeline At Pipex

Little-known Pipex Pharmaceuticals (PP ) may have a stable of winners in the making. Its lead drug Coprexa, which has completed two Phase III trials, has an "orphan drug" designation (for rare ailments) to treat neurologic Wilson's disease, a genetic metabolic disorder. Coprexa is set to be on the market by mid-2008, says Laurence Bleicher of Noble Financial. "This oral drug is already worth more than what Pipex' stock is selling for," he says. That comes on top of two other applications for Coprexa that Bleicher sees as big winners. One is a further oral formulation called Trimesta, for women with multiple sclerosis. It has completed Phase I/II trials, funded by a $5 million grant from the National Multiple Sclerosis Society and National Institutes of Health. Pipex is also developing Coprexa for idiopathic pulmonary fibrosis, which finished Phase I/II trials as well. High levels of copper result in such conditions, says Bleicher. Steven Winters, president of Gemini Strategies, which owns shares, says Pipex' drugs aimed at major markets are attracting investors. He sees the stock, now at 5.35, doubling in a year.

[BrauchGeld]

Pipex fliegt weiter nach oben aktuell 6,90 $ ( + 15% ) wohohohoho

[BrauchGeld]

Der Highflyer ist wieder unterwegs aktuell notiert PP bei 7,11$ obwohl die Aktie fast 100% zugelegt hat ist Pipex immer noch saubillig bewertet .

50-Day Moving Average3: 4.48
200-Day Moving Average3: 7.17 << knacken wir das ergibt sich weiteres aufwärts potential

[BrauchGeld]

jetzt geht aber die post ab

[BrauchGeld]

CEO muss ja ziemlich überzeugt sein von Pipex er gibt weitere 200.000$ für aktien aus.

23-Jul-07 KANZER STEVE H
Officer 29,700 Direct Purchase at $6.58 - $6.9 per share. $200,0002

[BrauchGeld]

Seeking Alpha
Pipex Pharmaceuticals Soars on Business Week Feature
Wednesday July 25, 5:50 am ET


Dan Pritch submits: Pipex Pharmaceuticals (AMEX: PP - News) is up 40% in the past week and nobody's even talking buyout. Interestingly, a news item in a large publication can amplify interest in a small stock like Pipex more than your typical holding.


The stock has been gradually rising for some time now, but on July 20, 2007, the stock rocketed 13% following a feature in Business Week's Inside Wall Street column. The next day, it continued to run, for a combined return of 41% over the past 5 sessions.

This influential column has a tendency to temporarily improve the fortunes of the companies it features. In fact, this column has been so influential in the past, that employees from a printing company which distributed the magazine were busted for insider trading because they were trading on the stocks highlighted prior to delivery of the magazine by the postal service. They amassed 6 figure profits until they were discovered.

Is now an optimal entry point? It's very tough to say given the speculative nature of a small biotech banking on approval of new drugs. The same stock dropped from 16 to 4 on Feb 14 - Happy Valentine's Day. But given the rationale outlined in the article, it has promise. And, given the momentum over the past week and lack of follow-on press, it's possible to see more big moves up in the coming days.

This case just highlights the result of influential coverage. The fundamentals of the company did not change overnight. There were no press releases divulging new information to the public. But up it went. Barron's, The Wall Street Journal and others have a similar effect now and then. The trick is picking which ones have merit, and won't return to their baseline in a few days.

[BrauchGeld]

Ist ja der wahnsinn wieder hat Kanzer zugeschlagen diesmal 8000st (~ 7,15$) für ca. 57000$ .....

http://secfilings.nasdaq.com/filingFrameset.asp?FileName=000…

[BrauchGeld]

Antwort auf Beitrag Nr.: 30.852.028 von BrauchGeld am 25.07.07 22:57:04

Und wieder greift CEO Kanzer zu diesmal 14300st für ~7,20$ macht rund 103.000$.
Übrigens Pipex CEO Kanzer und Präsident Bisgaier haben schonmal in der vergangenheit ein paar Unternehmen gegründet und erfolgreich weiter verkauft .

Esperion Therapeutics wurde an Pfizer für 1,3 Mrd$ verkauft
Developmental Therapeutics wurde von Titan Pharma übernommen



http://secfilings.nasdaq.com/filingFrameset.asp?FileName=000…

[BrauchGeld]

Pipex geht wieder ab und ich bin von anfang dabei yesssssssssssss

[BrauchGeld]

Pipex schliesst erneut kräftig im plus ,die aktie ist jetzt in den letzten 4 wochen um 100% gestiegen und trotzdem nach wie vor sehr unterbewertet .

http://finance.yahoo.com/q?s=pp